Corrigendum: First-in-human Phase 1 Dose-Escalation Results with Livmoniplimab, an Antibody Targeting the GARP: TGF-ß1 Complex, As Monotherapy and in Combination with the Anti-Pd-1 Antibody Budigalimab in Patients with Advanced Solid Tumors.
Frontiers in oncology（2025）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined